Tilray Inc. (NASDAQ: TLRY) shares dipped on Monday despite the cannabis firm announcing that it would be branching out and supporting two new clinical studies: one involving pediatric patients with severe behavioral problems (SBP) and intellectual disabilities (ID), and the other on immune activation in people living with HIV. Read More
